home / news / Four-year EuroQol initiative to help accelerate COVID-19 related research ends

Our Monthly Scientific Selection: October Publications on EuroQol Instruments #10

[1-31 October 2024] Stalmeier PFM, Roudijk B. What Makes the...

Our Monthly Scientific Selection: September Publications on EuroQol Instruments #9

[1-30 September 2024] Addo R, Mulhern B, Norman R, Owusu...

EQ-5D-Y-5L launched! A new EuroQol instrument providing children and adolescents with a wider range of options to describe their HRQoL

Launched as an approved EuroQol Group instrument today, the EQ-5D-Y-5L...

Our Monthly Scientific Selection: August Publications on EuroQol Instruments #8

[1-31 August 2024] Zhang G, Yang Z, Luo N, Wang...

The 18th Joint Call for Proposals by the EuroQol Working Groups is now OPEN!

The 18th Joint Call for Proposals by the EuroQol Working...

Four-year EuroQol initiative to help accelerate COVID-19 related research ends

Over the duration of the COVID-19 pandemic emergency, the EuroQol Research Foundation offered study-specific licenses free of charge to commercial users wishing to use EQ-5D instruments in studies aimed at testing COVID-19 treatments or diagnostic tools. During this period, numerous commercial organisations undertook COVID-19 related research around the world using EQ-5D instruments – with EuroQol forgoing license fees equivalent to more than € 1 million. 

Now that a year has passed since the World Health Organisation determined that the COVID-19 pandemic no longer constitutes a public health emergency of international concern, the EuroQol Board has decided that the time is right to end our COVID-19 research support initiative. From the 1st December 2024, licensing of EQ-5D instruments for use in the COVID-19 related studies will be aligned with EuroQol’s standard licensing policy